Significant Discovery of TRIM63 Gene in Hypertrophic Cardiomyopathy Enhances Early Diagnosis Potential

An Israeli research team has made a groundbreaking discovery identifying the TRIM63 gene as a crucial factor in hypertrophic cardiomyopathy (HCM), the most prevalent hereditary heart condition globally. This study, published in Circulation: Genomic and Precision Medicine, holds the potential to revolutionize genetic screening and treatment strategies for HCM patients worldwide.

Led by researchers from Rabin Medical Center and the Clalit Research Institute, the study presents compelling evidence regarding the gene's involvement in both the causation and increased susceptibility to HCM. Early identification of individuals with TRIM63 mutations could significantly enhance monitoring and intervention strategies, potentially reducing the risk of severe cardiac events.

Key findings from the study involved a thorough analysis of 107 unrelated patients diagnosed with HCM, utilizing advanced exome-based gene panels. The researchers examined diverse populations, including Ashkenazi Jews, Muslim Arabs, and various Jewish communities from North Africa and the Middle East. The study revealed:

• Biallelic pathogenic variants of TRIM63 were present in 4.7% of patients, accounting for 18.5% of all genetic diagnoses within the cohort. Patients with these variants displayed early-onset, severe heart muscle thickening along with frequent arrhythmias and episodes of fainting. Many required implantable defibrillators before receiving a definitive genetic diagnosis.
• Monoallelic pathogenic variants were identified in an additional 7.5% of patients. Compared to a control group without cardiac conditions, these variants were found to be 8.2 times more prevalent among HCM patients, indicating that even one defective copy of the TRIM63 gene significantly heightens the risk of developing the disease.
• A novel mutation (c.277C>T) was discovered to be relatively common among individuals of Libyan Jewish ancestry, with an estimated disease frequency of 1 in 14,400. This underscores the necessity for targeted genetic screening in genetically isolated or consanguineous populations.

These findings not only advance scientific understanding but also present a significant opportunity for preventive care among high-risk patients through personalized medical approaches. Despite the growing body of evidence supporting the role of TRIM63 in HCM, it is notably absent from many commercial genetic testing panels, primarily due to historical ambiguity regarding its significance. The current research provides a strong rationale for the immediate inclusion of TRIM63 in diagnostic protocols, especially within high-risk or underrepresented populations.

The study also emphasizes the advantages of exome-based genetic testing, which facilitates ongoing reanalysis and the straightforward addition of newly validated genes, providing greater flexibility than static gene-specific panels.

Integrating TRIM63 testing into standard HCM diagnostic processes could lead to:

• Earlier and more precise diagnoses for patients.
• Targeted monitoring for patients and their at-risk family members.
• Personalized treatment plans tailored to individual genetic risk factors.
• Enhanced clinical outcomes and improved quality of life for patients.

This research marks a significant advancement in cardiac genetics, establishing the TRIM63 mutation as a key risk factor for heart dysfunction. The findings are expected to have a far-reaching impact on millions of individuals globally, influencing both diagnostic practices and patient care.